AstraZeneca corrects financial-info accident; Strides eyes sale of Aussie generics unit;

@FiercePharma: Apparently BMS' strategy guy went out with a bang: $2.5B deal for hep C developer Inhibitex. News | Follow @FiercePharma

> AstraZeneca ($AZN) scrambled to reaffirm its Dec. 20 guidance figures after alternate numbers were mistakenly released to analysts. Report

> India's Strides Arcolab may sell off its Australian branded generics business, plus certain drug manufacturing units, to focus on specialty injectables. More

> Biogen Idec ($BIIB) says its 2012 goals include boosting Tysbri sales by better identifying patients at risk of side effects and expanding Fampyra's European footprint through additional launches. Release

> Indian officials will inspect 6 Chinese bulk-drug manufacturing facilities next month after complaints about manufacturing infractions. Story

> Sigma-Aldrich said it would buy bioharmaceutical testing services company BioReliance Holdings from the private equity firm Avistal Capital Partners for $350 million in cash. Item

> China's Fosun Pharmaceutical is eyeing an IPO in Hong Kong in March, aiming to raise $600 million to $800 million, Reuters says. News

> Indian analysts said an unattractive IPO market will prompt more private equity investment in domestic pharma this year. Story

Biotech News

@FierceBiotech: GSK, Theravance will file for approval of lung drug Relovair despite mixed batch of clinical data. Article | Follow @FierceBiotech

@JohnCFierce: Big biotech buyouts are fine, but I'd prefer a hot IPO market any day. And what are the chances of that this year? Article | Follow @JohnCFierce

@MarkHFierce: Two overexpressed genes + excess MeCP2 protein = anxious mice. Maybe someday this could help some anxious people. Story | Follow @MarkHFierce

@MaureenFierce: Greenpeace activist leading project to reduce vax spoilage in emerging markets using solar-powered coolers, fridges. Story | Follow @MaureenFierce

> Bristol bags hot hep C drug developer Inhibitex for $2.5B. News

> JPM kicks off with fevered focus on the next big biotech deal. More

Medical Device News

> Philips sues Zoll alleging infringement of patents covering defibrillators. Item

> Ventana inks separate companion Dx deals. More

> FDA: J&J, others must study safety of vaginal mesh. Story

> Cook to invest $21M in Ireland, eyes India for expansion. Article

Biotech IT News

> Knome taps Pfizer vet as new CEO. Article

> Accelrys CEO hints at more buyouts after VelQuest acquisition. News

> Bristol-Myers Squibb outsources network duties to British Telecom. Story

> Quintiles starts digital unit in online hunt for study patients. More

> New software aids RNA cocktail against cancer. Item

And Finally... The Obama administration filed its first set of briefs defending the 2010 healthcare reform law with the Supreme Court. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.